Q3 2020 Sales Performance

Increasing focus and prioritisation to support future growth Focus resources on key products Investing in priority markets Trelegy Nucala HIV Zejula Shingrix Bexsero gsk US China Building our capability in Specialty New talent with Specialty experience Co-location of development and commercial in Oncology Tesaro transaction Changes to our policy for working with healthcare professionals 18

View entire presentation